MDA-MB-231细胞

MDA-MB-231/MDA-MB-231细胞系/MDA-MB-231细胞株/MDA-MB-231人乳腺癌细胞

Cell line name MDA-MB-231

Synonyms MDA_MB_231; MDA-MB 231; MDA.MB.231; MDA MB 231; MDA MB231; MDA Mb231; MDA-MB231; MDAMB-231; MDAMB231; MDA-231; MDA-231P; MDA231; MDA231-BRE; MB231; MD Anderson-Metastatic Breast-231

Accession CVCL_0062

Resource Identification Initiative To cite this cell line use: MDA-MB-231 (RRID:CVCL_0062)

Comments Group: Triple negative breast cancer (TNBC) cell line.

Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: ENCODE project common cell types; tier 3.

Part of: JWGray breast cancer cell line panel.

Part of: ICBP43 breast cancer cell line panel.

Part of: JFCR39 cancer cell line panel.

Part of: JFCR45 cancer cell line panel.

Part of: KuDOS 95 cell line panel.

Part of: MD Anderson Cell Lines Project.

Part of: NCI-60 cancer cell line panel.

Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12532.

Registration: Chiron Master Culture Collection; CMCC 10583 (CMCC #10583).

Population: Caucasian.

Doubling time: 1.3 days (PubMed=9671407); 26.7 hours (PubMed=9815641); 24.7 hours (PubMed=24389870); 36.2 hours (PubMed=34238275); 38 hours (ATCC=HTB-26); ~25-30 hours (DSMZ=ACC-732); 41.9 hours (NCI-DTP=MDA-MB-231); ~38 hours (PBCF); 31.43 hours (JWGray panel).

Microsatellite instability: Stable (MSS) (PubMed=12661003; Sanger).

Omics: Array-based CGH.

Omics: Chromatin accessibility by ATAC-seq.

Omics: Cell surface proteome.

Omics: CNV analysis.

Omics: CRISPR phenotypic screen.

Omics: Deep exome analysis.

Omics: Deep proteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Exosome proteome analysis.

Omics: Fluorescence phenotype profiling.

Omics: Glycoproteome analysis by proteomics.

Omics: H2BK120ub ChIP-seq epigenome analysis.

Omics: H3K23ac ChIP-seq epigenome analysis.

Omics: H3K27ac ChIP-seq epigenome analysis.

Omics: H3K27me3 ChIP-seq epigenome analysis.

Omics: H3K36me3 ChIP-seq epigenome analysis.

Omics: H3K4me1 ChIP-seq epigenome analysis.

Omics: H3K4me3 ChIP-seq epigenome analysis.

Omics: H3K79me2 ChIP-seq epigenome analysis.

Omics: H3K9ac ChIP-seq epigenome analysis.

Omics: H3K9me3 ChIP-seq epigenome analysis.

Omics: H4K8ac ChIP-seq epigenome analysis.

Omics: lncRNA expression profiling.

Omics: Metabolome analysis.

Omics: miRNA expression profiling.

Omics: N-glycan profiling.

Omics: Protein expression by reverse-phase protein arrays.

Omics: Secretome proteome analysis.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Anecdotal: Used in a study utilising the fruit fly's olfactory system to detect cancer cells (PubMed=24389870).

Misspelling: MDA-MB-321; Note=Occasionally.

Misspelling: MDA-MD-231; Cosmic=1071900; Cosmic=1176602.

Misspelling: MDA-321; GEO=GSM459713.

Misspelling: MDA-MG-231; PubMed=6582512.

Misspelling: MD-MB-231; PRIDE=PXD010634.

Misspelling: MD-MBA-231; Note=Occasionally.

Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.

PubMed=6935474; DOI=10.1093/jnci/66.2.239

Wright W.C., Daniels W.P., Fogh J.

Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.

J. Natl. Cancer Inst. 66:239-247(1981)

 

PubMed=7272986; DOI=10.1016/0165-4608(81)90057-1

Satya-Prakash K.L., Pathak S., Hsu T.-C., Olive M., Cailleau R.M.

Cytogenetic analysis on eight human breast tumor cell lines: high frequencies of 1q, 11q and HeLa-like marker chromosomes.

Cancer Genet. Cytogenet. 3:61-73(1981)

 

PubMed=7459858

Rousset M., Zweibaum A., Fogh J.

Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.

Cancer Res. 41:1165-1170(1981)

 

PubMed=6582512; DOI=10.1073/pnas.81.2.568; PMCID=PMC344720

Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.

Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.

Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

 

PubMed=3518877; DOI=10.3109/07357908609038260

Fogh J.

Human tumor lines for cancer research.

Cancer Invest. 4:157-184(1986)

 

PubMed=3335022

Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Cancer Res. 48:589-601(1988)

 

PubMed=1961733; DOI=10.1073/pnas.88.23.10657; PMCID=PMC52989

Runnebaum I.B., Nagarajan M., Bowman M., Soto D., Sukumar S.

Mutations in p53 as potential molecular markers for human breast cancer.

Proc. Natl. Acad. Sci. U.S.A. 88:10657-10661(1991)

 

PubMed=7902062

de la Torre M., Hao X.-Y., Larsson R., Nygren P., Tsuruo T., Mannervik B., Bergh J.

Characterization of four doxorubicin adapted human breast cancer cell lines with respect to chemotherapeutic drug sensitivity, drug resistance associated membrane proteins and glutathione transferases.

Anticancer Res. 13:1425-1430(1993)

 

DOI=10.1016/B978-0-12-333530-2.50009-5

Leibovitz A.

Cell lines from human breast.

(In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York; USA (1994)

 

PubMed=8824553; DOI=10.1002/(SICI)1097-0215(19960917)67:6<816::AID-IJC10>3.0.CO;2-#

Mullen P., Ritchie A., Langdon S.P., Miller W.R.

Effect of Matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines.

Int. J. Cancer 67:816-820(1996)

 

PubMed=9815641

Wosikowski K., Schuurhuis D.H., Kops G.J.P.L., Saceda M., Bates S.E.

Altered gene expression in drug-resistant human breast cancer cells.

Clin. Cancer Res. 3:2405-2414(1997)

 

PubMed=9670966; DOI=10.4049/jimmunol.161.2.877

Bettinotti M.P., Kim C.J., Lee K.-H., Roden M., Cormier J.N., Panelli M.C., Parker K.K., Marincola F.M.

Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.

J. Immunol. 161:877-889(1998)

 

PubMed=9671407; DOI=10.1038/sj.onc.1201814

Sweeney K.J., Swarbrick A., Sutherland R.L., Musgrove E.A.

Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells.

Oncogene 16:2865-2878(1998)

 

PubMed=10700174; DOI=10.1038/73432

Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.

Systematic variation in gene expression patterns in human cancer cell lines.

Nat. Genet. 24:227-235(2000)